Pharmacyte Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated June 30, 2021, reports on the conclusion of the 2021 Annual Meeting of Stockholders for Pharmacyte Biotech, Inc. The meeting was originally held on June 16, 2021, and adjourned until concluded on June 30, 2021. The filing also documents corporate governance actions taken immediately following the meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Capital Structure: Following stockholder approval, the Company filed a Certificate of Amendment to its Articles of Incorporation on July 2, 2021. This increased the total number of authorized shares to 50,010,000,000.
- Share Designation: The authorized shares consist of 50,000,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock, both with a par value of $0.0001 per share.
- By-Laws: An amendment to the Company's by-laws was executed and filed as an exhibit.
Corporate Actions and Governance
Four proposals were approved by stockholders at the Annual Meeting:
- Election of Directors: Seven directors were elected to one-year terms, including Kenneth L. Waggoner, Gerald W. Crabtree, Thomas Liquard, Thomas C.K. Yuen, Michael M. Abecassis, Raymond C.F. Tong, and Carlos A. Trujillo.
- Authorized Share Increase: Stockholders approved the amendment to increase authorized common stock.
- Equity Incentive Plan: The 2021 Equity Incentive Plan was approved.
- Accounting Firm: The appointment of Armanino LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2022, was ratified.
Investor Verification Checklist
- Verify the impact of the 50 billion authorized share increase on potential future dilution.
- Review the specific terms of the newly approved 2021 Equity Incentive Plan.
- Confirm the details of the By-Laws amendment filed as Exhibit 99.2.
- Check subsequent filings for the issuance of any shares under the new authorization.